Determinants of antibody responses to two doses of ChAdOx1 nCoV-19 or BNT162b2 and a subsequent booster dose of BNT162b2 or mRNA-1273: population-based cohort study (COVIDENCE UK) [PDF]
David A. Jolliffe +17 more
openalex +1 more source
Supraclavicular lymphadenopathy secondary to COVID-19 BNT162b2 vaccine
Roca, B, Rambla, M, Roca, M Manuel
openaire +2 more sources
Longitudinal cellular and humoral immune responses after triple BNT162b2 and fourth full-dose mRNA-1273 vaccination in haemodialysis patients [PDF]
Matthias Becker +19 more
openalex +1 more source
New onset of pemphigus foliaceus following
Şebnem Yıldırıcı +3 more
openaire +3 more sources
Individual vaccine efficacy variation with time since mRNA BNT162b2 vaccination estimated by rapid, quantitative antibody measurements from a finger-prick sample [PDF]
Matheus J. T. Vargas +19 more
openalex +1 more source
CoronaVac or BNT162b2 Vaccine as a Third Dose
Rujittika Mungmunpuntipantip +1 more
openaire +2 more sources
Cutaneous reaction to BNT162b2 mRNA COVID‐19 vaccine [PDF]
Alba López‐Valle +2 more
openaire +3 more sources
Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naïve BNT162b2 vaccine recipients
Lorenzo Azzi +4 more
openalex +2 more sources
Incidences of Adverse Reactions in BNT162b2: A Meta-analysis [PDF]
Yi Dong +5 more
openalex +1 more source
Decline of immune humoral response after BNT162b2 vaccine
Sonia Ferri +8 more
openaire +4 more sources

